Caution With the Use of Lopinavir/Ritonavir in Severely Ill Patients for the Treatment of SARS-CoV-2: A Report of Severe Jaundice.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 32858566.
- Also identified by DOI 10.14309/ajg.0000000000000828 and PMC identifier 7473797.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We investigated the potential hepatotoxicity of lopinavir/ritonavir recently used in the treatment of Severe Acute Respiratory Syndrome Coronavirus. This is a retrospective cohort of critical patients in a teaching hospital: 12 treated with lopinavir/ritonavir and 30 in the standard-of-care group. Elevation occurred more frequently in patients treated with lopinavir/ritonavir (33% vs 6.7%). Caution is advised regarding the use of lopinavir/ritonavir in the most severe cases of Severe Acute Respiratory Syndrome Coronavirus.
Medical subject headings
- Antiviral Agents
- Coronavirus Infections
- Jaundice
- Lopinavir
- Pneumonia, Viral
- Ritonavir